水痘-带状疱疹病毒及其他三种疱疹病毒抗体与成人胶质瘤生存的关系
研究分析1378例1991至2010年诊断的成人胶质瘤患者诊断后血清IgG抗体与总生存的关系。水痘-带状疱疹病毒(VZV)抗体血清阳性与生存改善相关(HR=0.70,95%CI 0.54-0.90,P=.006),EBV抗体血清阳性亦与生存改善相关(HR=0.71,95%CI 0.53-0.96,P=.028);CMV和HSV抗体阳性与生存无关联。
要点
- VZV抗体血清阳性与成人胶质瘤生存改善相关(HR=0.70,95%CI 0.54-0.90,P=.006)。
- VZV抗体阳性者中,连续反应性高于第25百分位者生存优于低于者(HR=0.76,95%CI 0.66-0.88,P=.0003)。
- EBV抗体血清阳性与生存改善相关(HR=0.71,95%CI 0.53-0.96,P=.028),CMV和HSV抗体阳性与生存无关联。
核心结论
- 低水平VZV或EBV抗体与成人胶质瘤较差的生存结局相关,差异免疫反应而非病毒暴露可能解释这些发现。
研究设计与样本
- 分析1378例1991至2010年诊断的成人胶质瘤患者诊断后采集的血清IgG抗体,采血时间为术后中位3个月。
- 采用Cox模型估计IgG水平与总生存的关联,校正年龄、性别、自报种族、手术类型、采血时地塞米松使用和肿瘤分级。
- 模型按招募系列分层并荟萃分析以考虑时间依赖性治疗效应。
主要发现
- VZV抗体血清阳性与成人胶质瘤生存改善相关(HR=0.70,95%CI 0.54-0.90,P=.006)。
- VZV抗体阳性者中,连续反应性高于第25百分位者生存优于低于者(HR=0.76,95%CI 0.66-0.88,P=.0003)。
- EBV抗体血清阳性与生存改善相关(HR=0.71,95%CI 0.53-0.96,P=.028)。
- CMV和HSV抗体阳性与生存改变无关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lifetime exposure to the varicella-zoster virus (VZV) has been consistently inversely associated with glioma risk, however, the relationship of VZV with survival in adults with glioma has not been investigated. In this study, we analyzed the survival of adults with glioma in relation to their antibody measurements to 4 common herpes viral infections, including VZV, measured post-diagnosis. METHODS: We analyzed IgG antibody measurements to VZV, cytomegalovirus (CMV), herpes simplex virus 1/2 (HSV), and Epstein-Barr virus (EBV) collected from 1378 adults with glioma diagnosed between 1991 and 2010. Blood was obtained a median of 3 months after surgery. Associations of patient IgG levels with overall survival were estimated using Cox models adjusted for age, sex, self-reported race, surgery type, dexamethasone usage at blood draw, and tumor grade. Models were stratified by recruitment series and meta-analyzed to account for time-dependent treatment effects. RESULTS: VZV antibody seropositivity was associated with improved survival outcomes in adults with glioma (Hazard ratio, HR = 0.70, 95% Confidence Interval 0.54-0.90, P = .006). Amongst cases who were seropositive for VZV antibodies, survival was significantly improved for those above the 25th percentile of continuous reactivity measurements versus those below (HR = 0.76, 0.66-0.88, P = .0003). Antibody seropositivity to EBV was separately associated with improved survival (HR = 0.71, 0.53-0.96, P = .028). Antibody positivity to 2 other common viruses (CMV, HSV) was not associated with altered survival. CONCLUSIONS: Low levels of VZV or EBV antibodies are associated with poorer survival outcomes for adults with glioma. Differential immune response rather than viral exposure may explain these findings.
引用
- Guerra G, McCoy L, Hansen HM, et al. Antibodies to varicella-zoster virus and three other herpesviruses and survival in adults with glioma. Neuro Oncol. 2023. PMID: 36610073. doi:10.1093/neuonc/noac283
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。